Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle As Chief Business Officer

Dimension Therapeutics, Inc. ("Dimension" or the "Company"), a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, today announced that Mary Thistle, former senior vice president, business development at Cubist Pharmaceuticals, has been appointed to the newly created position of chief business officer. Ms. Thistle will report directly to Dimension's CEO Annalisa Jenkins, MBBS, MRCP, and her appointment is effective February 2.

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.